title: Immunosuppressive monoclonal antibodies: current and next generation.
abstract: Monoclonal antibodies (mAbs) are well-established therapeutics, as evidenced by the large number of Food and Drug Administration-approved mAbs for the treatment of cancers, and inflammatory or autoimmune diseases, and for the prevention and treatment of solid organ transplant rejection. Although, in many cases, mAbs have improved patient survival, they are also associated with an increased incidence of opportunistic infections. We review here the current and next generation of mAbs and the risks that infectious disease specialists should be aware of.
authors: U.O. Immuoematologia SSN, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. dfocosi@tin.it
authors: D
authors: D
authors: Focosi
authors: F
authors: F
authors: Maggi
authors: M
authors: M
authors: Pistello
authors: U
authors: U
authors: Boggi
authors: F
authors: F
authors: Scatena
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000139:chemically induced / Q000453:epidemiology*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents